COVID-19 Serologies Among Healthcare Workers at CHSD (SERO2)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06989307

Enrollment

447

Registered

2025-05-25

Start date

2021-03-01

Completion date

2021-06-01

Last updated

2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibodies, Viral, COVID-19, COVID-19 Serological Testing, COVID-19 Vaccines, Health Personnel, Seroepidemiologic Studies

Brief summary

This study looks at how many healthcare workers at CHSD hospital developed antibodies against COVID-19 after the second and third waves of the pandemic and after receiving a vaccine. It aims to better understand who might still be at risk of infection, how long immunity lasts after getting COVID or the vaccine, and how reliable previous antibody tests were. Blood samples will be collected from volunteer hospital staff during a one-month period to measure their antibody levels and compare them to earlier results.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

\- Volunteers from the hospital staff who have signed a new informed consent form

Exclusion criteria

* Refusal to participate (no signed consent form) * Staff unavailable during the blood sampling period * Participation only in the first seroprevalence survey without consent for the second

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 antibody prevalence (seroprevalence) among healthcare workers at CHSD	1 month (during the serological testing period)

Countries

France

Outcome results